Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Mounjaro® Injectable Pen
Group 19.png__PID:499bf244-8936-4f7e-bacb-0bc081a8cf6b

Mounjaro® Injectable Pen

GLP-1 Injectables Pens

  • Convenient weekly self injections
  • Promotes fullness and reduces appetite
  • Lose up to 20% of body weight effectively
  • No subscriptions, lowest price guarantee
£134.00
Get Started

Mounjaro® Facts

1 (1).jpg__PID:06478309-042c-42d8-a29e-678e73d7ae70

Our medical team are based in the UK and registered with the General Medical Council and General Pharmaceutical Council.

Active Ingredient

Tirzepatide

Indications

For adults with type 2 diabetes to improve blood sugar control, used alongside diet and exercise

Effectiveness

Clinical trials showed significant blood sugar reduction and weight loss in patients with type 2 diabetes

Warnings

Not recommended for use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Caution advised for patients with pancreatitis history or severe gastrointestinal disease

Mode of Action

Dual GIP and GLP-1 receptor agonist; enhances insulin secretion, reduces appetite, and increases feelings of fullness

Dosage

Weekly injection; initial dose of 2.5 mg, gradually increased based on patient response and tolerability

Side Effects

Nausea, diarrhoea, decreased appetite, vomiting, constipation, and abdominal pain

Lifestyle

Should be used in combination with a healthy diet and regular physical activity for optimal results

Comparison of Weight Loss Injectables

Features

Mounjaro®

Injectable Pen

Wegovy®

Injectable Pen

Saxenda®

Injectable Pen

Active Ingredient Tirzepatide Semaglutide Liraglutide
Mechanism of Action GLP-1 and GIP receptor agonist GLP-1 receptor agonist GLP-1 receptor agonist
Administration Weekly injection Weekly injection Daily injection
Dosage Varies by patient, typically starting low Varies, typically starting at 0.25 mg Varies, starting at 0.6 mg
Effect on Appetite Significantly reduces appetite and cravings Reduces appetite and increases satiety Reduces appetite and increases satiety
Average Weight Loss Up to 20% body weight reduction Up to 15% body weight reduction Significant weight reduction
Side Effects Nausea, vomiting, diarrhoea, constipation Nausea, vomiting, diarrhoea, constipation Nausea, diarrhoea, constipation, hypoglycemia
Approval FDA-approved for weight loss FDA-approved for weight loss FDA-approved for weight loss
Suitable For Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities

Our three-step approach

3.webp__PID:d9e8793a-bf4c-49a5-b423-1b366496c908

Quick Assessment

Skip GP and pharmacy trips with a 2-minute online assessment.

1.webp__PID:bf4cc9a5-b423-4b36-a496-c908bfef2d81

Select Treatment

Choose an effective weight loss treatment tailored for you.

2.webp__PID:4cc9a5b4-231b-4664-96c9-08bfef2d81e3

Discreet Delivery

Receive your treatment delivered in discreet packaging to your home.

frequently asked questions